九安医疗(002432) - 2017 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 148,641,365.26, down 6.59% year-on-year, while revenue for the year-to-date increased by 39.81% to CNY 475,437,035.29[7] - Net profit attributable to shareholders was a loss of CNY 39,559,416.91, an increase in loss of 27.92% compared to the same period last year[7] - The net cash flow from operating activities was a negative CNY 51,454,419.44, worsening by 27.96% year-on-year[7] - Basic and diluted earnings per share were both CNY -0.09, reflecting a 30.77% increase in loss compared to the same period last year[7] - The company reported a net loss of CNY 161,033,422.78, compared to a loss of CNY 73,601,317.46 in the previous period[33] - The company reported a cumulative net loss of CNY 19,282,705.08 for the year, compared to a loss of CNY 727,571.26 in the previous year, indicating a significant increase in losses[44] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,141,494,443.47, a decrease of 9.11% compared to the end of the previous year[7] - Total current assets decreased from CNY 1,493,180,210.63 to CNY 1,218,675,251.72, a decline of approximately 18.4%[30] - Total liabilities decreased from CNY 814,572,425.26 to CNY 729,332,530.73, a decline of approximately 10.5%[32] - The company’s total equity decreased from CNY 1,541,622,053.58 to CNY 1,412,161,912.74, a decline of approximately 8.4%[33] - The total liabilities increased to CNY 250,505,301.47 from CNY 218,388,709.39, marking a rise of 14.7%[39] Shareholder Information - The total number of shareholders at the end of the reporting period was 65,692[11] - The largest shareholder, Shihezi Sanhe Equity Investment Partnership, held 37.28% of the shares, totaling 161,338,702 shares[11] Cash Flow - The cash flow from operating activities showed a net outflow of CNY 121.12 million, an improvement from a net outflow of CNY 140.51 million in the same period last year[54] - The company reported a total cash outflow from operating activities of 424,344,636.83 CNY, compared to 357,329,048.11 CNY in the previous period, indicating an increase of about 18.7%[56] - The ending balance of cash and cash equivalents was 525,122,719.02 CNY, down from 605,088,054.01 CNY in the previous period, representing a decrease of about 13.2%[57] Revenue and Costs - Total operating revenue for Q3 2017 was CNY 148,641,365.26, a decrease of 6.9% from CNY 159,131,108.78 in the same period last year[38] - Cumulative operating revenue for the year reached CNY 475,437,035.29, up 39.9% from CNY 340,060,106.30 in the previous year[45] - Cumulative operating costs for the year were CNY 560,426,399.50, an increase of 28.4% from CNY 436,398,350.59[45] - Total operating costs for Q3 2017 were CNY 191,610,589.01, down from CNY 206,563,344.04, reflecting a cost reduction of approximately 7.2%[38] Investments and Market Presence - Long-term equity investments increased by 839.11% to ¥52.97 million due to the establishment of an overseas merger fund and investment in Hualai Technology[16] - The company sold over 1 million units of its products by the end of September 2017, significantly increasing its market presence[22] Other Financial Metrics - The weighted average return on net assets was -2.78%, a decrease of 1.01% compared to the previous year[7] - Non-recurring gains and losses amounted to CNY 1,612,897.39 for the year-to-date[8] - The company recorded a foreign exchange loss of CNY 42.01 million in the third quarter, compared to a gain of CNY 1.02 million in the previous year[48]